BMS-8

Description: BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 µM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers. Target: PD-1/PD-L1. Smiles: Cc1c(COc2ccc(CN3CCCCC3C(O)=O)cc2Br)cccc1-c1ccccc1. References: Gaudy-Marqueste C, Dussouil AS, Carron R, Troin L, Malissen N, Loundou A, Monestier S, Mallet S, Richard MA, Régis JM, Grob JJ. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. Eur J Cancer. 2017 Oct,84:44-54.